Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyQvia versus conventional subcutaneous immunoglobulin in multifocal motor neuropathy
2015-003453-18Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Human normal immunoglobulin G and subcuvia in multifocal motor neuropathy (MMN) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in muscle strength by isometric dynamometry. Started Sep 2015; status: completed.
02
Drugs
Human normal immunoglobulin Gsubcuvia
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2015-003453-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003453-18.